Category: Bacterial Infection

KENILWORTH, N.J.–(BUSINESS WIRE[1])–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by...

Posted at 18:11h in News[1] by WPD Staff[2] Today the World Fights Back Against the Leading Killer of Children: Pneumonia! “A league of global health experts, advocates, policymakers, and superheroes dressed in head-to-toe blue spandex supersuits fought back today against pneumonia – the world’s leading killer of children despite the existence of vaccines and medicines that could save a million...

Source/Disclosures [1] Disclosures: Nambiar is the director of the division of anti-infectives in the Office of Infectious Disease in FDA’s Center for Drug Evaluation and Research. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable...

For Immediate Release: June 04, 2020 On June 5, 2020 this press release was updated with information on the data that supported its approval for this indication. Today, the U.S. Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older....